Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain - PubMed (original) (raw)

Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain

Y Ye et al. J Neurochem. 1997 Dec.

Free article

Abstract

In a previous study, it was observed that the activity of rolipram-sensitive, low-Km, cyclic AMP phosphodiesterase (PDE4) was decreased in vivo with diminished noradrenergic stimulation. The results of the present experiments indicated that the reduction in the activity may be associated with down-regulation of PDE4 protein. Immunoblot analysis using PDE4-specific, subfamily-nonspecific antibody (K116) revealed four major bands of PDE4 in rat cerebral cortex; those with apparent molecular masses of 109 and 102 kDa are variants of PDE4A. Diminished noradrenergic activity, produced by intracerebroventricular infusion of 6-hydroxydopamine (6-OHDA) or chronic subcutaneous infusion of propranolol, decreased the intensities of the protein bands for the 109- and 102-kDa PDE4A variants in rat cerebral cortex but not of the 98- or 91-kDa PDE4 forms. 6-OHDA-induced noradrenergic lesioning also decreased the content of 102-kDa PDE4A in hippocampus as labeled by PDE4A-specific antibody (C-PDE4A). Enhanced noradrenergic stimulation up-regulated PDE4 in cerebral cortex. This was indicated by the finding that repeated treatment with desipramine increased the intensity of the protein band for the 102-kDa PDE4 but not for the other variants of PDE4. These results suggest that PDE4 subtypes are differentially regulated at the level of expression, as evidenced by an apparent change in the amount of PDE4 protein, following changes in noradrenergic activity. These observations are consistent with the notion that PDE4s, especially the PDE4A variants with molecular masses of 109 and 102 kDa, play an important role in maintaining the homeostasis of the noradrenergic signal transduction system in the brain and may be involved in the mediation of antidepressant activity.

PubMed Disclaimer

Similar articles

• Noradrenergic lesions differentially alter the expression of two subtypes of low Km cAMP-sensitive phosphodiesterase type 4 (PDE4A and PDE4B) in rat brain.
  Farooqui SM, Zhang K, Makhay M, Jackson K, Farooqui SQ, Cherry JA, O'Donnell JM. Farooqui SM, et al. Brain Res. 2000 Jun 9;867(1-2):52-61. doi: 10.1016/s0006-8993(00)02224-1. Brain Res. 2000. PMID: 10837797
• Ontogeny of rolipram-sensitive, low-K(m), cyclic AMP-specific phosphodiesterase in rat brain.
  Zhang K, Farooqui SM, O'Donnell JM. Zhang K, et al. Brain Res Dev Brain Res. 1999 Jan 11;112(1):11-9. doi: 10.1016/s0165-3806(98)00150-3. Brain Res Dev Brain Res. 1999. PMID: 9974155
• Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.
  Zhang HT. Zhang HT. Curr Pharm Des. 2009;15(14):1688-98. doi: 10.2174/138161209788168092. Curr Pharm Des. 2009. PMID: 19442182 Review.
• 4-(3-Cyclopentoxy-4-[11C]methoxy-phenyl)pyrrolidin-2-one.
  Leung K. Leung K. 2006 Jan 12 [updated 2008 Jan 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2006 Jan 12 [updated 2008 Jan 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641301 Free Books & Documents. Review.

Cited by

• Changes in NMDA receptor-induced cyclic nucleotide synthesis regulate the age-dependent increase in PDE4A expression in primary cortical cultures.
  Hajjhussein H, Suvarna NU, Gremillion C, Chandler LJ, O'Donnell JM. Hajjhussein H, et al. Brain Res. 2007 May 29;1149:58-68. doi: 10.1016/j.brainres.2007.02.090. Epub 2007 Mar 12. Brain Res. 2007. PMID: 17407767 Free PMC article.
• Gαs, adenylyl cyclase, and their relationship to the diagnosis and treatment of depression.
  Schappi JM, Rasenick MM. Schappi JM, et al. Front Pharmacol. 2022 Nov 18;13:1012778. doi: 10.3389/fphar.2022.1012778. eCollection 2022. Front Pharmacol. 2022. PMID: 36467104 Free PMC article. Review.
• Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior.
  Bolger GB, Smoot LHM, van Groen T. Bolger GB, et al. Int J Mol Sci. 2020 Aug 9;21(16):5704. doi: 10.3390/ijms21165704. Int J Mol Sci. 2020. PMID: 32784895 Free PMC article.
• Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.
  Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS. Takahashi M, et al. J Neurosci. 1999 Jan 15;19(2):610-8. doi: 10.1523/JNEUROSCI.19-02-00610.1999. J Neurosci. 1999. PMID: 9880581 Free PMC article.
• The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.
  Schaal SM, Garg MS, Ghosh M, Lovera L, Lopez M, Patel M, Louro J, Patel S, Tuesta L, Chan WM, Pearse DD. Schaal SM, et al. PLoS One. 2012;7(9):e43634. doi: 10.1371/journal.pone.0043634. Epub 2012 Sep 19. PLoS One. 2012. PMID: 23028463 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley